CD
NBIX icon

Carl Domino’s Neurocrine Biosciences NBIX Stock Holding History

Carl Domino’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-9,000
Closed -$509K – 145
2015
Q4 		$509K Hold
9,000
– – 0.4% 68
2015
Q3 		$358K Hold
9,000
– – 0.29% 75
2015
Q2 		$430K Hold
9,000
– – 0.29% 75
2015
Q1 		$357K Sell
9,000
-2,000
-18% -$71.5K 0.27% 83
2014
Q4 		$246K Sell
11,000
-4,000
-27% -$75.8K 0.13% 134
2014
Q3 		$235K Hold
15,000
– – 0.13% 138
2014
Q2 		$223K Buy
15,000
+4,000
+36% +$56.4K 0.11% 153
2014
Q1 		$177K Sell
11,000
-3,200
-23% -$54.7K 0.09% 162
2013
Q4 		$133K Hold
14,200
– – 0.07% 164
2013
Q3 		$161K Sell
14,200
-2,500
-15% -$34.4K 0.09% 153
2013
Q2 		$223K Buy
+16,700
New +$205K 0.13% 127

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Carl Domino's NBIX Position: Q1 2016 in Review

Carl Domino sold out of Neurocrine Biosciences (NBIX) in Q1 2016, closing a stake of 9,000 shares — an estimated $509K sold.

Carl Domino first reported a position in NBIX in Q2 2013 and held it in 11 quarters. The position peaked at $509K in Q4 2015. 212 funds tracked by Wall St. Rank hold NBIX as of Q1 2016.

  • Carl Domino reported no remaining Neurocrine Biosciences position as of Q1 2016 after selling out during the quarter.
  • Carl Domino sold 9,000 Neurocrine Biosciences shares in Q1 2016, an estimated $509K.
  • Carl Domino first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 11 quarters.
  • Carl Domino's Neurocrine Biosciences position peaked at $509K in Q4 2015.
  • 212 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2016.

Based on Carl Domino's 13F filing for Q1 2016, filed 19 Apr 2016.